# # # #
Novel therapeutic interventions are being proposed for Parkinson’s on a regular basis, with compelling data supporting their future development.
The case is strengthened when a measure of target engagement is also involved – providing not only a potential therapy but also a biomarker as well.
Recently, a biotech company called AcureX Therapeutics has been presenting just such a case, based on a biological mechanism involving the protein Miro1.
In today’s post, we will discuss what Miro1 is and how it might be useful for future clinical trials.
# # # #
Watching the recent Michael J Fox Foundation‘s Progress in the PD Pipeline webinar (Wednesday 10th November, 2021), I was really impressed by the presentation by Dr Bill Shrader (co-founder and CEO/CSO of AcureX Therapeutics)
In particular, I really liked their approach to potential patient selection for future clinical trials of their lead drug candidate. It all revolves around the analysis of Miro1 as a biomarker.
What is Miro1?